



Elevate the standard of cervical cancer screening

HPV extended genotyping is an innovative screening tool to enhance clinical management.

Individual identification of high-risk genotypes is essential to reveal the true risk of CIN3+ disease*.¹


Partial genotyping:

Only 2 high-risk HPV types individually identified



Extended genotyping with BD Onclarity™ HPV Assay:

6 high-risk HPV types individually identified




Individual results



Pooled results

BD Onclarity™ HPV Assay has officially been added to the ASCCP guidelines

The American Society for Colposcopy and Cervical Pathology (ASCCP) has separated the BD Onclarity™ HPV Assay channels into three different risk-based tiers, which inform new clinical recommendations.²



It's time to redefine screening and make powerful progress towards
eliminating cervical cancer

Learn more at bd.com/onclarity

*CIN, cervical intraepithelial neoplasia.

[†]Note: Dual Stain is not FDA approved for use as a triage with BD Onclarity™ HPV Assay

References:

1. Bonde JH et al. *J Low Genit Tract Dis*. 2020;24(1):1–13.
2. ASCCP. *Management Guidelines and the Enduring Guidelines Process*. Accessed February 2025.

bd.com

BD, the BD logo, and Onclarity are trademarks of Becton, Dickinson and Company or its affiliates. All other trademarks are the property of their respective owners. ©2025 BD. All rights reserved. (BD-145682 4355-WW-0925 September 2025)

